Drugs / pyroxamide
pyroxamide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00042900 | Apr → Sep 2002 | leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, plasma cell neoplasm +2 | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pyroxamide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00042900 ↗ |
| Known as | NSC 696085 | “A Phase I Clinical And Pharmacological Study Of Pyroxamide (NSC 696085) In Patients With Advanced Malignancies” NCT00042900 ↗ |
| Known as | Octanedioic acid hydroxyamide pyridin-3-ylamide | ChEMBL registry synonym — accepted as the source's own label CHEMBL353581 ↗ |
| Modality | Small molecule | — CHEMBL353581 ↗ |
| Route | Intravenous | “Patients receive pyroxamide IV continuously over 5-7 days.” NCT00042900 ↗ |